NEW YORK, December 30, 2025, 03:31 ET — Market closed
- Pfizer shares were last at $25.00, down about 0.3% from the prior close, in after-hours trading.
- Wall Street ended lower on Monday as tech stocks slipped; traders are watching Fed minutes and jobless claims next.
- Weight-loss drug pricing stayed in focus after Novo Nordisk and Eli Lilly flagged cuts in China.
Pfizer Inc (PFE) shares were last down 0.3% at $25.00 in after-hours trading, after ending Monday at $25.09. The stock traded between $24.98 and $25.19 in the regular session.
With U.S. markets in the final stretch of the year, volumes typically thin and position-adjusting can drive short-term moves. That leaves investors leaning more on the next clear catalyst than on day-to-day headlines.
Wall Street’s main indexes ended lower on Monday as megacap tech shares retreated, and traders have the minutes from the Federal Reserve’s last meeting and weekly jobless claims on the near-term calendar. Reuters
Pfizer on Dec. 16 provided full-year 2026 guidance, forecasting adjusted earnings per share — profit per share excluding certain one-time items — of $2.80 to $3.00 and revenue of $59.5 billion to $62.5 billion. The company also flagged a roughly $1.5 billion year-over-year drop in COVID-19 product revenue and another roughly $1.5 billion headwind tied to loss of exclusivity. “2025 was a year of strong execution and strategic progress for Pfizer,” Chief Executive Albert Bourla said. Pfizer
Loss of exclusivity refers to the point when a medicine’s patent or regulatory protection ends, typically opening the door to cheaper generic or biosimilar competition and pressuring sales.
Investors also kept an eye on obesity-drug competition after Novo Nordisk and Eli Lilly said they were lowering prices of their top-selling weight-loss drugs Wegovy and Mounjaro in China. Novo confirmed it is adjusting Wegovy pricing, while a hospital WeChat account said Mounjaro prices would fall from Jan. 1. Reuters
The coming wave of weight-loss pills is also pushing the market toward more cash-pay and direct-to-consumer channels, with drugmakers and telehealth platforms positioning for a broader base of users, Reuters reported. Reuters
For Pfizer, the big-picture question remains whether newer products and acquired assets can offset patent expirations while the company keeps spending disciplined and hits its cost targets.
Before the next session, focus turns to Pfizer’s next scheduled company-wide update: its fourth-quarter 2025 results briefing on Feb. 3. The company is slated to host a conference call with analysts at 10 a.m. ET that day, according to its investor relations calendar. Pfizer Investor Relations
Income-focused investors are also tracking Pfizer’s dividend timeline. Pfizer declared a $0.43 first-quarter 2026 dividend, payable March 6 to shareholders of record on Jan. 23. Pfizer
